Fidelity Investments
XLO icon

Fidelity Investments’s Xilio Therapeutics XLO Stock Holding History

Fidelity Investments’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$307K Sell
36,558
-1
-0% -$8 ﹤0.01% 3310
2025
Q4 		$328K Hold
36,559
– – ﹤0.01% 3237
2025
Q3 		$431K Hold
36,559
– – ﹤0.01% 3084
2025
Q2 		$348K Sell
36,559
-26,586
-42% -$281K ﹤0.01% 3107
2025
Q1 		$640K Sell
63,145
-36,559
-37% -$459K ﹤0.01% 2834
2024
Q4 		$1.33M Hold
99,704
– – ﹤0.01% 2574
2024
Q3 		$1.1M Hold
99,704
– – ﹤0.01% 2568
2024
Q2 		$1.32M Sell
99,704
-36,558
-27% -$572K ﹤0.01% 2447
2024
Q1 		$2.06M Hold
136,262
– – ﹤0.01% 2327
2023
Q4 		$1.05M Hold
136,262
– – ﹤0.01% 2463
2023
Q3 		$4.03M Hold
136,262
– – ﹤0.01% 2105
2023
Q2 		$5M Hold
136,262
– – ﹤0.01% 2065
2023
Q1 		$6.07M Hold
136,262
– – ﹤0.01% 2031
2022
Q4 		$5.13M Sell
136,262
-22,292
-14% -$752K ﹤0.01% 2109
2022
Q3 		$6.46M Sell
158,554
-21,541
-12% -$836K ﹤0.01% 2083
2022
Q2 		$7.36M Sell
180,095
-4,957
-3% -$262K ﹤0.01% 2106
2022
Q1 		$18.3M Buy
185,052
+1,461
+0.8% +$231K ﹤0.01% 1819
2021
Q4 		$41.1M Buy
+183,591
New +$43.8M ﹤0.01% 1498

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments's XLO Position: Q1 2026 in Review

Fidelity Investments reduced its Xilio Therapeutics (XLO) stake by 0% in Q1 2026, selling an estimated $8 and leaving 36,558 shares worth $307K. The position accounts for ﹤0.01% of the portfolio, ranked #3310.

Fidelity Investments first reported a position in XLO in Q4 2021 and has held it in 18 quarters since. The position peaked at $41.1M in Q4 2021. 24 funds tracked by Wall St. Rank hold XLO as of Q1 2026.

  • Fidelity Investments held 36,558 shares of Xilio Therapeutics worth $307K as of Q1 2026.
  • Fidelity Investments sold 1 Xilio Therapeutics share in Q1 2026, an estimated $8.
  • Xilio Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #3310 holding.
  • Fidelity Investments first reported a position in Xilio Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • Fidelity Investments's Xilio Therapeutics position peaked at $41.1M in Q4 2021.
  • 24 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.